PM frequencies of major CYPs in Asians and Caucasians

Drug Metabolism Reviews

Volumn 35, Issue 2-3, 2003, Pages 99-106

  Mizutani, Takaharu ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Asians; Caucasians; CYP; CYP2A6; CYP2C19; CYP2C9; CYP2D6; CYP3A4; Cytochrome p450; Poor metabolizer

Indexed keywords

ADENOSINE 3' PHOSPHATE 5' PHOSPHOSULFATE; AMITRIPTYLINE; CODEINE; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEBRISOQUINE; DEXTROMETHORPHAN; DICLOFENAC; FLECAINIDE; GLUTATHIONE; IBUPROFEN; IMIPRAMINE; LOSARTAN; MEPHENYTOIN; NIFEDIPINE; OMEPRAZOLE; PARACETAMOL; PHENYTOIN; QUINIDINE; QUINOLINE; RITONAVIR; TAMOXIFEN; TOLBUTAMIDE; UNINDEXED DRUG; URIDINE DIPHOSPHATE GALACTOSE; WARFARIN;

ASIAN; CAUCASIAN; DRUG EFFICACY; DRUG METABOLISM; ENZYME POLYMORPHISM; ENZYME SPECIFICITY; GENE FREQUENCY; HUMAN; LIVER METABOLISM; POPULATION RESEARCH; PROTEIN FAMILY; RACE DIFFERENCE; REVIEW; TOXICITY;

EID: 0042357440     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-120023681     Document Type: Review

References (31)

1. Aithel, G. P., Day, C. P., Leathart, J. B. S., Daly, A. K. (2000). Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 10:511-518.
2. Ariyoshi, N., Takahashi, Y., Miyamoto, M., Umetsu, Y., Daigo, S., Tateishi, T., Kobayashi, S., Mizorogi, Y., Loriot, M.-A., Stucker, I., Beaune, P., Kinoshita, M., Kamataki, T. (2000). Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmocogenetics 10:687-693.
3. Evans, W. E., Relling, M. V. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491.
4. Griese, E.-U., Ilett, K. F., Kitteringham, N. R., Eichelbaum, M., Powell, H., Spargo, R. M., LeSouef, P. N., Musk, A. W., Minchin, R. F. (2001). Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia. Pharmacogenetics 11:69-76.
5. Guengerich, F. P., Miller, G. P., Hanna, I. H., Martin, M. V., Leger, S., Black, C., Chauret, N., Silva, J. M., Trimble, L. A., Yergey, J. A., Nicoll-Griffith, D. A. (2002). Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry 41:11025-11034.
6. Hirano, Y., Uehara, M., Saeki, K., Kato, T., Takahashi, K., Mizutani, T. (2002). The influence of quinolines on coumarin 7-hydroxylation in bovine liver microsomes and human CYP2A6. J. Health Sci. 48:118-125.
7. Hiroi, T., Imaoka, S., Funae, Y. (1998). Dopamine formation from Tyramine by CYP2D6 Biochem. Biophys. Res. Commun. 249:838-843.
8. Hsien, K.-P., Lin, Y.-Y., Cheng, C.-L., Lai, M.-L., Lin, M.-S., Siest, J.-P., Huang, J.-D. (2001). Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos. 29:268-273.
9. Ingelman-Sundberg, M. (2001). Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development. Drug Metab. Dispos. 29:570-573.
10. Kaneko, A., Kaneko, O., Taleo, G., Bjorkman, A., Kabayakawa, T. (1997). High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet 349:921-922.
11. Kaneko, A., Bergqvist, Y., Taleo, G., Kabayakawa, T., Ishizaka, T., Bjorkman, A. (1999a). Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. Pharmacogenetics 9:317-326.
12. Kaneko, A., Lum, J. K., Yaviong, J., Takahashi, N., Ishizaki, T., Bertilsson, L., Kabayakawa, T., Bjorkman, A. (1999b). High and variable frequencies of CYP2C 19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics 9:581-590.
13. Kubota, T., Chiba, K., Iga, T. (2001). Frequency distribution of CYP2C19 and CYP2C9 mutant-alleles in several different populations. Xenobio. Metabol. Dispos. 16:69-74, (in Japaneese).
14. Kwon, J. T., Nakajima, M., Chai, S., Yom, Y.-K., Kim, H.-K., Yamazaki, H., Sohn, D.-R., Yamamoto, T., Kuroiwa, Y., Yokoi, T. (2001). Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics 11:317-323.
15. Miyamoto, M., Umetsu, Y., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Kunitoh, H., Nemoto, N., Sato, K., Ariyoshi, N., Kamataki, T. (1999). CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun. 261:658-660.
16. Nakajima, M., Yokoi, T., Mizutani, M., Kinoshita, M., Funayama, M., Kamataki, T. (1999). Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. 125:803-808.
17. Nelson, D., Kamataki, T., Waxman, D. J., Guengerich, F. P., Estabrook, R. W., Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. C., Gotoh, O., Okuda, K., Nebert, D. W. (1993). The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12:1-51.
18. Nielsen, T. L., Rasmussen, B. B., Flinois, J.-P., Beaune, P., Brosen, K. (1999). In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-450 3A4 activity in human liver microsomes. J. Pharmcol. Exp. Ther. 289:31-37.
19. Omura, T. (1999). Forty years of cytochrome P450. Biochem. Biophys. Res. Commun. 266:690-698.
20. Omura, T., Sato, R. (1962). The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem. 237:1375-1376.
21. Osacarson, M., McLellan, R. A., Gullstein, H., Agundez, J. A. G., Benitez, J., Rautio, A., Raunio, H., Pelkonen, O., Ingelman-Sundberg, M. (1999a). Identification and characterization of novel polymorphisms in the CYP2A locus: implication for nicotine metabolism. FEBS Lett. 460:321-327.
22. Oscarson, M., McLellan, R. A., Gullstein, H., Yue, Q.-Y., Lang, M. A., Bernal, M. L., Sinues, B., Hirvonen, A., Raunio, H., Pelkonen, O., Ingelman-Sundberg, M. (1999b). Characterization and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 448:105-110.
23. Ozdemir, V., Kalow, W., Tang, B.-K., Paterson, A. D., Walker, S. E., Endrenyi, L., Kashuba, A. D. M. (2000). Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388.
24. Ramamoorthy, Y., Tydale, R. F., Sellers, E. M. (2001). Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11:477-487.
25. Sachse, C., Brockmoller, J., Bauer, S., Roots, I. (1997). Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic concequences. Am. J. Hum. Genet. 60:284-295.
26. Shimada, T., Tsumura, F., Yamazaki, H., Guengerich, F. P., Inoue, K. (2001). Characterization of (+)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics 11:143-156.
27. Sueyoshi, T., Negishi, M. (2001). Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu. Rev. Pharmacol. Toxicol. 41:123-143.
28. 359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10:95-104.
29. Wei, P., Zhang, J., Egan-Hafley, M., Liang, S., Moore, D. D. (2000). The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 407:920-923.
30. Wrighton, S. A., Ring, B. J. (1998). Predicting drug interactions and pharmocokinetics variability with in vitro methods: the olazapine experience. Drug Metab. Rev. 30:15-28.
31. Xie, W., Barwick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., Neuschwander-Tetri, B. A., Brunt, E. M., Guzelian, P. S., Evans, R. M. (2000). Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435-439.